SBI links with Chinese biotech for nucleotide drugs
This article was originally published in Scrip
The Japanese bioventure SBI Biotech has entered into a collaboration with China's Changchun Huapu Biotechnology to develop novel nucleotide therapeutics. The deal gives SBI certain rights to co-develop three Changchun projects in markets including the US, China and/or Japan. Changchun has developed a novel class of therapies which target dendritic and malignant B-cells and modulate immune response. SBI intends to investigate the possible combination of these with antibodies and other immunotherapies, president and CEO Dr Ken-ichi Araisaid.
You may also be interested in...
New potential topical therapy in dermatitis space set to move towards Japan approval submission based on positive new results.
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.